<DOC>
	<DOCNO>NCT02476955</DOCNO>
	<brief_summary>An Open-label Phase 1b Study ARQ 092 Combination Carboplatin Plus Paclitaxel , Combination Paclitaxel , Combination Anastrozole Subjects Selected Solid Tumors</brief_summary>
	<brief_title>Open-label Phase 1b Study ARQ 092 Combination With Carboplatin Plus Paclitaxel , Combination With Paclitaxel , Combination With Anastrozole</brief_title>
	<detailed_description>This open-label Phase 1b , dose escalation study oral ARQ 092 administer combination carboplatin plus paclitaxel ( Carboplatin Plus Paclitaxel Arm ) combination paclitaxel alone ( Paclitaxel Arm ) subject advanced , inoperable metastatic and/or recurrent solid tumor , combination anastrozole ( Anastrozole Arm ) subject ovarian endometrial cancer .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . Signed write informed consent form 2 . 18 year age old 3 . Histologically cytologically confirm locally advance , inoperable , metastatic tumor : • Carboplatin Plus Paclitaxel Arm : Subjects tumor type ( except lung ) carboplatin plus paclitaxel chemotherapy would appropriate • Paclitaxel Arm : Subjects tumor type ( except lung ) paclitaxel chemotherapy would appropriate • Anastrozole Arm : Subjects ovarian endometrial cancer : Documented/locally determine AKT1 PIK3CA mutation ER+ status 4 . Female subject childbearing potential must negative serum urine pregnancy test within 72 hour prior administration first dose study drug . `` Women childbearing potential '' define sexually mature woman undergone hysterectomy and/or bilateral oophorectomy , naturally postmenopausal least 12 consecutive month prior administration first dose study drug . 5 . Measurable evaluable disease 6 . Subjects must agree provide archival and/or fresh tissue biopsy sample , available . Tumor biopsy do subject lesion , opinion Investigator , non minimally invasive tumor biopsy may perform . 7 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 8 . Life expectancy ≥ 12 week 9 . Failure respond refractory approved/standard therapy ; standard therapy exist , tolerable ; approved/standard therapy consider sufficient appropriate Investigator . • Carboplatin Plus Paclitaxel Arm : Subjects previously treat carboplatin paclitaxel locally advance and/or metastatic disease receive last dose drug ( ) ≥ 12 month prior first dose study treatment may enrol Subjects previously treat carboplatin paclitaxel locally advance and/or metastatic disease , opinion Investigator , chemotherapy regimen appropriate may enrol • Paclitaxel Arm : Subjects previously treat paclitaxel locally advance and/or metastatic disease opinion Investigator may benefit combination treatment ARQ 092 paclitaxel may enrol Subjects previously treat paclitaxel locally advanced and/or metastatic disease , opinion Investigator , chemotherapy regimen appropriate may enrol 10 . Adequate organ function indicate follow laboratory value . All laboratory test must obtain within 7 day prior first dose study treatment : Hematological Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L ( Carboplatin Plus Paclitaxel Arm Paclitaxel Arm ) ≥ 1.0 x 109/L ( Anastrozole Arm ) Platelet count ( Plt ) ≥ 100 x 109/L Hemoglobin ( Hb ) ≥ 9 g/dL ( Carboplatin Plus Paclitaxel Arm Paclitaxel Arm ) ≥ 8 g/dL ( Anastrozole Arm ) Renal Serum creatinine ≤ 1.5 x upper limit normal ( ULN ) Calculated creatinine clearance ≥ 60 mL/min /1.73 m2 subject serum creatinine level &gt; 1.5 x institutional ULN Hepatic Total bilirubin ≤ 1.5 x ULN Direct bilirubin ≤ ULN subject total bilirubin level &gt; 1.5 x ULN AST ALT ≤ 3 x ULN ≤ 5 x ULN subject know liver metastasis Metabolic Glycated hemoglobin ( HbA1c ) ≤ 8 % 11 . If subject currently receive bisphosphonates denosumab , subject must receive bisphosphonates denosumab least four week start study treatment . ( Initiation bisphosphonates denosumab study may allow provide subject completes first cycle treatment without DLT Investigator rule tumor progression . ) 12 . Male female subject childbearing potential must agree use doublebarrier contraceptive measure , oral contraception , avoidance intercourse study ( six month last dose paclitaxel 3 month last dose ARQ 092 whichever long ) 1 . Anticancer therapy , chemotherapy , immunotherapy , target hormonal/endocrine therapy , investigational agent within two week oral drug , four week intravenous drug , six week nitrosoureas , mitomycin C , bevacizumab prior administration first dose study drug To eligible study treatment , toxicity prior treatment must recover Grade ≤ 1 , except alopecia Concurrent systemic highdose corticosteroid use intermittently antiemetic regimen central nervous system ( CNS ) metastases management part premedication regimen allow For subject enrol Carboplatin Plus Paclitaxel Arm Paclitaxel Arm , concurrent standard longterm anticancer hormonal therapy drug include limited selective estrogen receptor modulators Gonadotropinreleasing hormone ( GnRH ) analog start least six month first dose study treatment allow 2 . Radiation therapy within four week prior administration first dose study drug • To eligible study treatment , radiation therapyrelated toxicity must recover Grade ≤ 1 prior administration first dose study drug . Concurrent palliative radiotherapy local paincontrol may allow , provide subject meet criterion progressive disease treat lesion include target/nontarget lesion assessment . 3 . Major surgical procedure within four week prior administration first dose study drug • To eligible study treatment , surgical wound must fully heal surgeryrelated adverse event ( AE ) must recover Grade ≤ 1 4 . Previous treatment AKT inhibitor ( e.g. , MK2206 , GSK2141795 , AZD5363 ) 5 . Contraindications treatment : Carboplatin and/or paclitaxel define Investigator base Food Drug Administration ( FDA ) approve label institutional standard care ( SOC ) Anastrozole define Investigator base institutional SOC , scientific evidence , expert medical judgment , publish literature 6 . History allergic reaction attribute compound ( ) similar chemical biologic composition ARQ 092 , carboplatin , paclitaxel , anastrozole 7 . Unable unwilling swallow ARQ 092 anastrozole comply chemotherapy regimen 8 . Known active CNS metastasis and/or carcinomatous meningitis • To eligible study treatment , subject must stable disease ≥ 3 month , confirm magnetic resonance imaging ( MRI ) compute tomography ( CT ) scan , CNS metastases well control lowdose steroid , antiepileptic , symptomrelieving medication 9 . History myocardial infarction ( MI ) congestive heart failure define Class II IV per New York Heart Association ( NYHA ) classification within 6 month first dose ARQ 092 ( MI occur &gt; 6 month prior first dose ARQ 092 permit ) 10 . History Type 1 2 diabetes mellitus require regular medication ( oral hypoglycemic agent include metformin ) fast glucose ≥ 160 mg/dL 11 . Significant gastrointestinal disorder ( ) , could opinion Investigator , interfere absorption , metabolism , excretion ARQ 092 ( e.g. , Crohn 's disease , ulcerative colitis , extensive gastric resection ) 12 . Previous malignancy within 2 year first dose study drug , except tumor totally resect and/or require therapy 13 . Concurrent uncontrolled illness related cancer , include limited : • Ongoing active infection , include human immunodeficiency virus ( HIV ) , hepatitis B ( HBV ) ( hepatitis B surface antigen [ HBsAg ] positive ; subject document laboratory evidence HBV clearance may enrol ) hepatitis C ( HCV ) ( positive HCV antibody ) , bleed 14 . Psychiatric illness , substance abuse , and/or social situation would limit compliance study requirement 15 . Blood transfusion within 5 day blood draw use confirm eligibility 16 . Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>ARQ 092</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>AKT inhibitor combination therapy</keyword>
	<keyword>Targeted therapy</keyword>
	<keyword>Molecular therapy</keyword>
	<keyword>Tyrosine kinase inhibitor ( TKI )</keyword>
	<keyword>Receptor tyrosine kinase ( RTK )</keyword>
	<keyword>Biomarkers</keyword>
	<keyword>Phase 1 - Phase I</keyword>
	<keyword>Solid tumor</keyword>
	<keyword>Metastatic solid tumor</keyword>
	<keyword>Recurrent solid tumor</keyword>
	<keyword>Ovarian cancer</keyword>
	<keyword>Endometrial cancer</keyword>
	<keyword>Cervical cancer</keyword>
	<keyword>Triple-negative breast cancer</keyword>
	<keyword>AKT kinase</keyword>
	<keyword>AKT pathway</keyword>
	<keyword>AKT signal</keyword>
	<keyword>AKT inhibitor</keyword>
	<keyword>AKT pan inhibitor</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>PI3K/AKT/mTOR signal pathway</keyword>
	<keyword>AKT1</keyword>
	<keyword>AKT2</keyword>
	<keyword>AKT3</keyword>
	<keyword>Phase I Clinical Trial</keyword>
	<keyword>Clinical oncology</keyword>
	<keyword>Tumor</keyword>
	<keyword>AKT1 inhibitor</keyword>
	<keyword>AKT2 inhibitor</keyword>
	<keyword>AKT3 inhibitor</keyword>
	<keyword>AKT1 mutation</keyword>
	<keyword>AKT2 mutation</keyword>
	<keyword>AKT3 mutation</keyword>
	<keyword>AKT1 amplification</keyword>
	<keyword>AKT2 amplification</keyword>
	<keyword>AKT3 amplification</keyword>
	<keyword>Anastrozole</keyword>
	<keyword>Estrogen receptor positive</keyword>
</DOC>